Литература. 
Эффекты винпоцетина на перераспределение церебрального кровотока и метаболизма глюкозы у больных с хроническими нарушениями мозгового кровообращения – данные позитрон-эмиссионной томографии

1. Bonoczk P., Gulyas B., Adam-Vizi V., Nemes A., Karpati E., Kiss B. et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine // Brain Res Bull 2000; 53: 245−54.

2. Biro K., Karpati E., Szporny L. Protective activity of ethyl apovincaminate on ischemic anoxia of the brain // Arzneim-Forsch 1976; 26: 1918;20.

3. Miyamoto M., Murphy T.H., Schnaar R.L. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line // J. Pharmacol Exp Ther 1989; 250: 1132−40.

4. Tohgi H., Sasaki K., Chiba K., Nozaki Y. Effect of vinpocetinee on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type // Arzneim-Forsch 1990; 40: 640−3.

5. Tretter L., Adam-Vizi V. The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes // Neuroreport 1998; 9: 1849−53.

6. Bukanova Y.V., Solntseva E.L. Nootropic agent vinpocetine blocks delayed rectified potassium currents strongly than high-threshold calcium currents // Neurosci Behav Physiol 1998; 28: 116−20.

7. Erdo S., Molnar P., Lakics V., Bence J.Z., Tomoskozi Z. Vincamine and vincanol are potent blockers of voltage-gated Na+ channels // Eur J. Pharmacol 1996; 314: 69−73.

8. Molnar P., Erdo S.L. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons // Eur J. Pharmacol 1995; 273: 303−6.

9. Kiss B., Cai N.S., Erdo S.L. Vinpocetine preferentially antagonizes quisqualate / AMPA receptor responses: evidence from release and ligand binding studies // Eur J. Pharmacol 1991; 209: 109−12.

10. Krieglstein J., Rischke R. Vinpocetine increases the neuroprotective effect of adenosine in vitro // Eur J. Pharmacol 1991; 205: 7−10.

11. Rischke R., Krieglstein J. Effects of Vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischaemia in the rat // Pharmacology 1990; 41: 153−60.

12. Rischke R., Krieglstein J. Protective effect of Vinpocetine against brain damage caused by ischaemia // Jpn J. Pharmacol 1991; 56: 349−56.

13. Jucker M., Meier-Ruge W., Baettig K. Relative regional changes in 2-deoxyglucose uptake reflect cognitive performances in aged and adult rats. Effects of brovincamine and Vinpocetine // Psychopharmacology 1988; 96: 29.

14. Miyazaki M. The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases // Angiology 1995; 46: 53−8.

15. Kuzuya F. Effects of vinpocetinee on platelet aggregability and erythrocyte deformability // Ther Hung 1958; 33: 22−34.

16. Szobor A., Klein M. Examinations of the relative fluidity in cerebrovascular disease patients // Ther Hung 1991; 40: 8−11.

17. Hayakawa M. Effect of vinpocetinee on red blood cell deformability in vivo measured by a new centrifiigation method // Arzneim-Forsch 1992; 42: 281−3.

18. Hayakawa M. Effect of vinpocetinee on red blood cell deformability in stroke patients // Arzneim-Forsch 1992; 42: 425−7.

19. Bereczki D., Fekete I. Vinpocetine for acute ischemic stroke // Cochrane Database Syst Rev 2000; 2: CD000480.

20. Bonoczk P., Panczel G., Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study // Eur J. Ultrasound 2002; 15: 85−91.

21. Gulyas B., Halldin C., Karlsson P., Chou Y.H., Swahn C.G., Farde L. Brain uptake and plasma metabolism of C-vinpocetine. A PET-study in cynomolgus monkey // J. Neuroimaging 1999; 9: 217−22.

22. Gulyas B., Halldin C., Sandell J., Swahn C.G., Bonock P., Kiss B. et al. PET studies on the uptake and regional distribution of [11C] vinpocetine in human subjects // Acta Neurol Scand 2002; 106: 325−32.

23. Gulyas B., Sovago J., Sandell J., Halldin C., Cselenyi Z.M., Vas A. et al. Drug distribution in man: a positron emission tomography study after oral administration of the labelled europrotective drug vinpocetine // Eur J. Nucl Med Mol Imaging 2002; 29: 1031−8.

24. Gulyas B., Vas A., Halldin C., Sovago J., Sandell J., Fredriksson A. et al. Cerebral uptake of [ethyl-11C] vinpocetine and l-[HC] ethanol in cynomolgous monkeys: a comparative preclinical PET study // Nucl Med Biol 2002; 29: 753−9.

25. Hall H., Varnas K., Sandell J., Halldin C., Farde L., Vas A. et al. Autoradiographic evaluation of [11C] vinpocetine binding in the human postmortem brain // Acta Biol Hung 2002; 53: 59−66.

26. Gulyas B., Csiba L., Kerenyi L., Galuska L., Tron L. The effect of a single-dose intravenous vinpocetine on chronic stroke patients. A PET study. In: Gulyas B, Muller-Gartner HW, editors. Positron emission tomography: a critical assessment of recent trends // Dordrecht: Kluwer Academic Publishers; 1998. p. 291−306.

27. Szakall S., Boros I., Balkay L., Emri M., Fekete I., Kerenyi L. et al. The cerebral effects of a single dose intravenous vinpocetine in chronic stroke patients: a PET study // J. Neuroimaging 1998; 8: 197−204.

28. Helsinki Declaration // Br Med J. 1964 (18 July): 177.

29. Orgogozo J.M. Evaluation of treatments in ischemic-stroke patients. In: Amery WK, editor. Clinical trial methodology in stroke. London: Malliere Tindall; 1989. p. 35−53.

30. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol // Stroke 1985; 16: 885−90.

31. Loewen S.C., Anderson B.A. Reliability of the modified motor assessment scale and the barthel index // Phys Ther 1988; 68: 1077−81.

32. Gresham G.E., Phillips T.F., Labi M.L. ADL status in stroke: relative merits of three standard indexes // Arch Phys Med Rehabil 1980; 61: 355−8.

33. Greitz T., Bergstrom M., Boothius J, Kingsley D, Ribbet T. Head fixation device for integration of radiodiagnostic and radiotherapeutic procedures // Neuroradiology 1980; 19: 1−6. 34. Bergstr5m M, Boethius J, Eriksson J, Greitz T, Ribbe T, Widen L. Head fixation device for reproducible positron alignment in transmission CT and positron emission tomography // J. Comput Assist Tomogr 1981; 5: 136−41.

35. Phelps M.E., Huang S.C., Hoffman E.J., Selin C., Sokoloff L., Kuhl D.E. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2 -fluoro-2-deoxy-D-glucose: validation of method // Ann Neurol 1979; 6: 371−88.

36. Huang S.C., Phelps M.E., Hoffman E.J. Noninvasive determination of local cerebral glucose metabolic rate in man // Am J. Physiol 1980; 238: E69−82.

37. Roland P.E., Friberg L. Localization of cortical areas activated by thinking // J. Neurophys 1985; 53: 1219−43.

38. Rota-Kops E., Herzog H., Schmid A., Holte S., Feinendegen L.E. Performance characteristics of an eight-ring whole body PET scanner // J. Comput Assist Tomogr 1990; 14: 437−45.

39. Berridge M.S., Cassidy E.H., Terris A.H. A routine, automated synthesis of oxygen-15-labeled butanol for positron tomography // J. Nucl Med 1990; 31: 1727−31.

40. Kuwabara H., Evans A.C., Gjedde A. Michaelis-Menten constrains improved cerebral glucose metabolism and regional lumped constant measurement with F18-fluorodeoxyglucose // J. Cereb Blood Flow Metab 1990; 110: 180−9.

41. Balkay L., Molnar T., Boros I., Lehel S., Galambos T. Quantification of FDG uptake using kinetic models. In: Gulyas B., Muller-Gartner H.W., editors. Positron emission tomography: a critical assessment of recent trends // Dordrecht: Kluwer; 1998. p. 153−62.

42. Woods R.P., Cherry S.R., Mazziotta J.C. Rapid automated algorithm for aligning and reslicing PET images // J. Comput Assist Tomogr 1992; 16: 620−33.

43. Emri M., Marian T., Kover G. Registration: a powerful tool to combine information provided by different imaging modalities. In: Gulyas B, Muller-Gartner HW, editors. Positron emission tomography: a critical assessment of recent trends // Dordrecht: Kluwer; 1997. p. 143−51.

44. Ohta S., Meyer E., Fujita H., Reutens D.C., Evans A., Gjedde A. Cerebral [15O] water clearance in humans determined by PET: I. Theory and normal values // J. Cereb Blood Flow Metab 1996; 16: 765−80.

45. Roland P.E., Graufelds C.J., Wahlin J., Ingelman L., Andersson M., Ledberg A. et al. Human Brain Atlas: for high-resolution functional and anatomical mapping // Hum Brain Mapp 1994; 1: 173−84.

46. Talairach J., Tournoux P. Coplanar stereotaxic atlas of the human brain. Stuttgart: Thieme Verlag; 1988.

47. Metry G., Wikstrom B., Valind S., Sandhagen B., Linde T., Beshara S. et al. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients // J. Am Soc Nephrol 1999; 10: 854−63.

48. Brun J.F., Bouchahda C., Chaze D., Benhaddad A.A., Micallef J.P., Mercier J. The paradox of hematocrit in exercise physiology: which is the «normal» range from an hemorheologist’s viewpoint? // Clin Hemorheol Microcirc 2000; 22: 287−303.

49. Shackford S.R., Zhuang J., Schmoker J. Intravenous fluid tonicity: effect on intracranial pressure, cerebral blood flow, and cerebral oxygen delivery in focal brain injury // J. Neurosurg 1992; 76: 91−8.

50. Voorhees III W.D., Ralston S.H., Kougias C., Schmitz P.M. Fluid loading with whole blood or Ringer’s lactate solution during CPR in dogs // Resuscitation 1987; 15: 113−23.

51. Marchal G., Young A.R., Baron J.C. Early postischemic hyperperfusion: pathophysiologic insights from positron emission tomography // J. Cereb Blood Flow Metab 1999; 19: 467−82.

52. Bentourkia M., Bol A., Ivanoiu A., Labar D., Sibomana M., Coppens A. et al. Comparison of regional cerebral blood flow and glucose metabolism in the normal brain: effect of aging // J. Neurol Sci 2000; 181: 19−28.

53. Willis M.W., Ketter T.A., Kimbrell T.A., George M.S., Herscovitch P., Danielson A.L. et al. Age, sex and laterality effects on cerebral glucose metabolism in healthy adults // Psychiatry Res Neuroimaging 2002; 114: 23−37.

54. Cave A.S., Ingwal J.S., Friedrich J., Liao R., Saupe K.W., Apstein C.S. et al. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate // Circulation 2000; 101: 2090;6.

55. Gjedde A., Marrett S., Vafaee M. Oxidative and nonoxidative metabolism of excited neurons and astrocytes // J. Cereb Blood Flow Metab 2002; 22: l-14.

56. Matkovics B., Szabo L., Kiss B., Szporny L. Effect of ethyl apovincaminate on the utilization of 14C glucose by rat brain in vitro. Arzneim-Forsch / Drug Res 1991; 41: 107−8.

57 Shibota M., Kakihana M., Nagaoka A. The effect of vinpocetine on the brain glucose uptake in mice // Folia Pharmacol Jpn 1982; 80: 221−4.

58. Kakihana M., Suno M., Hamajo K., Nagaoka A., Shibota M. Protective effect of vinpocetine on experimental brain ischaemia // Folia Pharmacol Jpn 1982; 80: 225−9.

59. Hossmann J.C.A. Viability thresholds and the penumbra of focal ischemia // Ann Neurol 1994; 36: 557−65.

60. Selman W.R., Lust W.D., Pundik S., Zhou Y., Ratcheson R.A. Compromised metabolic recovery following spontaneous spreading depression in the penumbra // Brain Res 2004; 999: 167−74.

61. Huber M., Kittner B., Hojer C., Fink G.R., Neveling M., Heiss W.D. Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke // J. Cereb Blood Flow Metab 1993; 13: 526−30.

62. Wang G.J., Volkow N.D., Overall J., Hitzemann R.J., Pappas N., Pascani K. et al. Reproducibility of regional brain metabolic responses to lorazepam // J. Nucl Med 1996; 37: 1609−13.

63. Schaefer S.M., Abercrombie H.C., Lindgren J.C.A., Larson C.L., Ward R.T., Oakes T.R. et al. Six-month test-retest reliability of MRI-defined PET measures of regional cerebral glucose metabolic rate in selected subcortical structures // Hum Brain Mapp 2000; 10: 1−9.